Make Michigan Progressive Again.

Get the 2020 Michigan Progressive Voters Guide and find out which candidates on your personal ballot are dedicated to supporting progressive politics and equality and justice for all Americans.

Get My Voter Guide

New era of HIV/AIDS treatment on the horizon

By |2007-03-08T09:00:00-05:00March 8th, 2007|News|

by Bob Roehr

Two new classes of drugs treating HIV are likely to be approved later this year by the FDA. Many consider it to be a milestone second only to the introduction of the powerful combination therapies more than a decade ago. The mounting evidence of the success of these new therapies, created an exuberant atmosphere at the 14th retroviral conference, Feb. 25-28.
In the first class, Maraviroc is a CCR5 inhibitor that blocks specific types of HIV from entering a cell. It is taken in pill form twice daily. Fuzeon (T-20), an injectable in this class, is also taken twice daily and acts at the same point in the virus’ lifecycle.
The first pair of trials involved patients with very advanced disease who had failed drugs in all three of the approved classes of anti-retrovirals and had a viral load greater than 5000.
They also had to be tested to see if they have the R5-tropic version of HIV, which uses the CCR5 coreceptor to enter the cell. About half of all patients who were screened had the R5 virus, the remainder had the virus that either used the CXCR4 receptor (X4-tropic) or had a mix of the two viruses (dual-tropic).
Physicians in the trial used resistance data to create an individualized optimized background therapy (OBT) and then the patients were randomized to receive a placebo or Maraviroc once or twice a day.
At the end of 24 weeks, more than half of the patients on Maraviroc had a viral load that was below 400 copies, compared with less than a third of those who received only OBT plus placebo. Their CD4 cell counts increased by more than 100, twice as much as the increase of those in the placebo arm of the study.
“Patients receiving Maraviroc were twice as likely, in both studies independently, to achieve an undetectable HIV-1 RNA, compared with the best available regimen. The studies were remarkably consistent in this regard,” said Howard Mayer, MD. He led the team at Pfizer that developed Maraviroc.
Plus, the side effects were at least as manageable as the placebo group.
“Even though patients on Maraviroc were on therapy longer because they didn’t fail as much as patients in the placebo groups, the adverse events profile looked remarkably similar,” Mayer said.
“This is important news for people who need salvage therapy regimens,” said Daniel Kuritzkes, MD, Director of AIDS Research at Brigham and Women’s Hospital in Boston who did not participate in the trials.
“Even though we have new protease drugs like Tipranavir and Darunavir, there are already large numbers of patients who have the virus which is partly resistant to those protease inhibitors. Many people don’t want to be on an injectable, so T-20 is not an option for them,” he said.
Rob Camp, with the community-based Treatment Action Group, applauded Pfizer for toning down the hype, particularly with regard to safety data.
“Instead of concluding, ‘so it is safe,’ they very responsibly pointed out the short term of therapy so far, and promised to ‘continue reviewing the data to identify the frequency and severity of infections.'”
The long term effect of blocking the CCR5 receptor is not known and that is likely to be the central topic of ongoing monitoring when an FDA advisory committee meets on April 24 to review approval of Maraviroc. But those questions are not likely to hold up approval which should come in June.

Raltegravia by end of year?

The other major new class of drugs are Integrase inhibitors. They prevent HIV from inserting itself into the DNA of the cell to crank out more copies of the virus.
Raltegravir (MK-0518) by Merck, is the farthest along. Again, the patients in the twin ongoing trials were heavily treatment experienced, having developed resistance to all three approved classes of drugs. An OBT was put together and patients were randomized to receive either placebo or Raltegravir twice a day.
David Cooper, MD, with the Australia National HIV Center, presented a 24-week interim analysis showing that 43 percent suppressed their viral load below 400 on the OBT plus placebo arm, compared to 79 percent on Raltegravir. Side effects were about the same in both groups.
Part of the reason why the OBT performed so well is that the study allowed use of unapproved drugs as part of the regimen, in this instance Darunavir which was then available through expanded access and has since been approved. Roughly 20 percent of patients in the slightly earlier study incorporated Darunavir into their regimen and that rose to about 50 percent in the second study that started a bit later.
The principle weakness to Raltegravir, and possibly to the entire class of integrase inhibitors, is that resistance can develop fairly easily. Cooper said. “My understanding is that there is no cross resistance,” with any of the approved classes of drugs. He cautioned against reading any clinical relevance into these findings because of the relatively small number of patients and short duration use of the drug.
Merck is preparing to submit Raltegravir to the FDA for approval, which may come by the end of 2007.
Gilead Sciences presented data on its integrase inhibitor, Elvitegravir, which is in an earlier stage of development. It looks to be about as effective in terms of suppressing the virus and has a similar profile of side effects. Unfortunately, the same resistance mutations seem to develop with both drugs in the class.
John Mellors, MD, vice chair of the conference, was rhapsodic about the new classes of drugs.
“When HAART initially came out, the response [of viral load below 400 copies] was in the 60 to 80 percent range among treatment naive patients. To see the same results with these new drugs in highly treatment experienced patients is really a remarkable development.”
Kuritzkes was a bit more restrained. “What clinicians need to be doing with their experienced patients is assessing patient’s clinical status carefully and not leap to introduce any one of the new drugs until they are convinced they can put together a fully active regimen.”
That may mean using an expanded access program, or holding off until the drug becomes available.
“You really need to use these drugs in combination, whenever possible,” add Kuritzkes.

About the Author:

BTL Staff
Between The Lines has been publishing LGBTQ-related content in Southeast Michigan since the early '90s. This year marks the publication's 27th anniversary.